Valproate is associated with early decrease of high-density lipoprotein cholesterol levels in the psychiatric population.

Détails

Ressource 1Télécharger: Manuscript_Delacrétaz 2021_Valproate HDL (1) couv serval.pdf (1032.99 [Ko])
Etat: Public
Version: Author's accepted manuscript
Licence: Non spécifiée
ID Serval
serval:BIB_EBB73A5FE75D
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Valproate is associated with early decrease of high-density lipoprotein cholesterol levels in the psychiatric population.
Périodique
Basic and clinical pharmacology and toxicology
Auteur⸱e⸱s
Delacrétaz A., Glatard A., Dubath C., Gholam M., Gamma F., von Gunten A., Conus P., Eap C.B.
ISSN
1742-7843 (Electronic)
ISSN-L
1742-7835
Statut éditorial
Publié
Date de publication
07/2021
Peer-reviewed
Oui
Volume
129
Numéro
1
Pages
26-35
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Few studies have evaluated the influence of valproate on the deterioration of the lipid profile in psychiatric patients. This observational study aimed to compare the evolution of metabolic parameters in a sample of adult patients starting valproate (n = 39) with a control group (n = 39) of patients starting aripiprazole, a drug associated with a low risk of metabolic deterioration. Data were obtained from a prospective study including psychiatric patients with metabolic parameters monitored during the first year of treatment. During the first month of treatment with valproate (median: 31 days [IQR: 25-36]), mean body mass index increased significantly (from 24.8 kg/m <sup>2</sup> at baseline to 25.2 kg/m <sup>2</sup> after one month; P = .03) and mean HDL-C levels decreased significantly (from 1.39 mmol/L to 1.27 mmol/L; P = .02). In comparison, these metabolic variables remained stable during the first month of treatment with aripiprazole. The proportion of patients with early (ie during the first month of treatment) HDL-C decrease of ≥ 5% was significantly higher under valproate (54%) than aripiprazole (15%) treatment (P < .001). These findings remind the importance of a prospective metabolic monitoring in patients who initiate valproate treatment. Further research should be conducted on larger samples and should focus on finding effective interventions to prevent such metabolic adverse effects.
Mots-clé
anticonvulsants, dyslipidaemia, epilepsia, obesity, psychopharmacology
Pubmed
Web of science
Création de la notice
30/03/2021 13:46
Dernière modification de la notice
01/11/2022 7:16
Données d'usage